SRRK Stock Forecast & Price Target

Scholar Rock Holding is attractive because its wholly owned, approved therapy ISEMBYLD gives the company a rare commercial asset in a standalone mid-cap biotech, with higher net pricing expectations of about $310k per patient per year supporting an increased 2035E revenue estimate of $2.2B from $1.9B. The recent approval meaningfully de-risks the story, as indicated by the move in probability of success from 95% to 100%, while management and the market view the fracture-risk language in the label as relatively benign and unlikely to materially limit uptake. Beyond the approved product, the pipeline still offers additional upside through the subcutaneous formulation of apitegromab, SRK-439, and early-stage neuromuscular programs, giving the company multiple shots at expanding value in rare, severe diseases.

Scholar Rock Holding is facing a fundamentally challenged commercial and valuation setup because the core SMA fracture narrative remains unproven, with even key opinion leaders lacking a measured baseline natural-history fracture rate and likely needing several years of real-world Isembyld use before any durable change in perception. Despite management’s expectation of roughly $310K in annual net revenue per typical patient and about $454K in annual gross WAC before discounts and rebates, uptake may be constrained by payer friction, step edits, duration-on-SMN2 therapy requirements, prescription-to-infusion delays, and the uncertainty of how a backbone add-on therapy will be reimbursed in practice. The company also still faces meaningful execution risk around access logistics, infusion-site availability, and future label-expansion support from OPAL and ONYX data, making the commercial runway dependent on proof that current physician enthusiasm can translate into sustained, reimbursed demand.